About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2026№2

Modern strategies for maintaining women’s health: an interdisciplinary view

DOI
https://dx.doi.org/10.18565/aig.2026.36

Teterina T.A., Apolikhina I.A., Yarmolinskaya M.I., Balashova Kh.B.

1) Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Moscow, Russia; 3) D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductive Medicine, St. Petersburg, Russia; 4) I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, St. Petersburg, Russia

The article presents an overview of the fundamental principles outlined in FIGO 2025 and ECSVD 2025 which reflect modern strategies for maintaining women’s health. It covers the updated approaches to the management of chronic pelvic pain (including the FIGO-IPPS “R U MOVVING SOMe” classification), primary ovarian failure (POF), genitourinary syndrome of menopause (GSM), non-hormonal therapy of menopausal symptoms, and non-surgical treatment of urinary incontinence.
Special attention is paid to an interdisciplinary and patient-oriented approach to the management of women with POF and postmenopausal women in accordance with the current recommendations of ESHRE, BMS and NAMS. The article presents clinical observations of patients with GSM after oncogynecological treatment and POF, demonstrating the effectiveness of a combined approach that includes systemic hormone therapy (if there are no contraindications), topical remedies and correction of intimate hygiene.
The paper emphasizes the strategic transition of modern gynecology to a personalized model of management of women’s health throughout the life course with a focus on quality of life.
Conclusion: FIGO 2025 marked the strategic transition of global gynecology, namely from the treatment of complications to the management of women’s health throughout life, from surgical correction to regenerative and functional therapy, from protocols to personalized medicine. At the same time, the emergence of regenerative and aesthetic trends indicates that women’s health is considered not only in terms of survival, but also with regard to quality of life.

Authors’ contributions: Apolikhina I.A., Yarmolinskaya M.I. – processing and analysis of the materials, writing the text, editing the material of the article; Teterina T.A., Balashova Kh.B. – collecting publications, processing and analysis of the materials, writing the text, translation of articles.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Teterina T.A., Apolikhina I.A., Yarmolinskaya M.I., Balashova Kh.B. 
Modern strategies for maintaining women’s health: an interdisciplinary view.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (2): 140-150 (in Russian)
https://dx.doi.org/10.18565/aig.2026.36

Keywords

chronic pelvic pain
primary ovarian failure
genitourinary syndrome of menopause
postmenopause
urinary incontinence
sexual dysfunction
Full text (in Russian)

References

  1. XXV FIGO World Congress of Gynecology and Obstetrics, 5-9 October 2025. Available at: https://www.who.int/news-room/events/detail/2025/10/05/default-calendar/xxv-figo-world-congress-of-gynecology-and-obstetrics
  2. Advancing women’s health: a journey of unity and freedom. Available at: https://figo2025.org/programme/?utm_source=chatgpt.com
  3. A Global Rally Calling for Stronger Maternal Health: FIGO 2025 Highlights. Available at: https://laerdalglobalhealth.com/Resources/news/figo-2025-highlights/
  4. World Health Organization. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage. 2025. Available at: https://www.who.int/publications/i/item/9789240115637
  5. Lamvu G., Villegas-Echeverri J.D., Allaire C., As-Sanie S., Carrillo J., Khalil S. et al. Developing the FIGO‐IPPS «RU MOVVING SOMe» classification system for female chronic pelvic pain. Int. J. Gynecol. Obstet. 2025; 171(2): 550-65. https://dx.doi.org/10.1002/ijgo.70522
  6. Chronic pelvic pain: ACOG Practice Bulletin, number 218. Obstet. Gynecol. 2020; 135(3): e98-e109. https://dx.doi.org/10.1097/AOG.0000000000003716
  7. Rice K., Connoy L., Webster F. Gendered worlds of pain: women, marginalization, and chronic pain. J. Pain. 2024; 25(11): 104626. https://dx.doi.org/10.1016/j.jpain.2024.104626
  8. Villegas-Echeverri J.D., Robert M., Carrillo J.F., Green I., Meinhold-Heerlein I., Attar R. et al. FIGO–IPPS consensus statement: addressing the global unmet needs of women with chronic pelvic pain. Int. J. Gynecol. Obstet. 2025; 169(3): 1140-5. https://dx.doi.org/10.1002/ijgo.70093
  9. Kingsberg S., Banks V., Caetano C., Janssenswillen C., Moeller C., Schoof N. et al. Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: findings from the REALISE study. Maturitas. 2024; 189: 108096. https://dx.doi.org/10.1016/j.maturitas.2024.108096
  10. Pinkerton J.V., Simon J.A., Joffe H., Maki P.M., Nappi R.E., Panay N. et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024; 332(16): 1343-54. https://dx.doi.org/10.1001/jama.2024.14618
  11. Gurunanselage Don R.A.S., Yap M.K.K. Arctium lappa L. root extract induces cell death via mitochondrial-mediated caspase-dependent apoptosis in Jurkat human leukemic T cells. Biomed. Pharmacother. 2019; 110: 918-29. https://dx.doi.org/10.1016/j.biopha.2018.12.023
  12. Zhang B., Li M., Qiao Y., Gao P, Li L., Zheng Z. Potential use of low-field nuclear magnetic resonance to determine the drying characteristics and quality of Arctium lappa L. in hot-blast air. LWT. 2020; 132: 109829. https://dx.doi.org/10.1016/j.lwt.2020.109829
  13. Lee J., Ha S.J., Park J., Kim Y.H., Lee N.H., Kim Y.E. et al. Arctium lappa root extract containing L-arginine prevents TNF-α-induced early atherosclerosis in vitro and in vivo. Nutr. Res. 2020; 77: 85-96. https://dx.doi.org/10.1016/j.nutres.2020.03.003
  14. Andritoiu C.V., Andriescu C.E., Ibanescu C., Lungu C., Ivanescu B., Vlase L. et al. Effects and characterization of some topical ointments based on vegetal extracts on incision, excision, and thermal wound models. Molecules. 2020; 25(22): 5356. https://dx.doi.org/10.3390/molecules25225356
  15. Tobyn G., Denham A., Whitelegg M. Arctium lappa, burdock. 2011; 91-103. In: Medical Herbs. https://dx.doi.org/10.1016/B978-0-443-10344-5.00015-X
  16. Miglani A., Manchanda R.K. Observational study of Arctium lappa in the treatment of acne vulgaris. Homeopathy. 2014; 103(3): 203-7. https://dx.doi.org/10.1016/j.homp.2013.12.002
  17. Yosri N., Alsharif S.M., Xiao J., Musharraf S.G., Zhao C., Saeed A. et al. Arctium lappa (Burdock): insights from ethnopharmacology potential, chemical constituents, clinical studies, pharmacological utility and nanomedicine. Biomed. Pharmacotherapy. 2023; 158: 114104. https://dx.doi.org/10.1016/j.biopha.2022.114104
  18. Moro T.M.A., T P S Clerici M. Burdock (Arctium lappa L) roots as a source of inulin-type fructans and other bioactive compounds: current knowledge and future perspectives for food and non-food applications. Food Res. Int. 2021; 141: 109889. https://dx.doi.org/10.1016/j.foodres.2020.109889
  19. García-Gamboa R., Domínguez-Simi M.Á., Gradilla-Hernández M.S., Bravo-Madrigal J., Moya A., González-Avila M. Antimicrobial and antibiofilm effect of inulin-type fructans, used in synbiotic combination with Lactobacillus spp. against candida albicans. Plant Foods Hum. Nutr. 2022; 77(2): 212-9. https://dx.doi.org/10.1007/s11130-022-00966-3
  20. García-Gamboa R., Domínguez-Simi M., Gradilla-Hernández M.S., Bravo J., Moya A., Ruiz-Álvarez B. et al. Anticandidal and antibiofilm effect of synbiotics including probiotics and inulin-type fructans. Antibiotics (Basel). 2022; 11(8): 1135. https://dx.doi.org/10.3390/antibiotics11081135
  21. Aehle E., Müller U., Eklund P.C., Willför S.M., Sippl W., Dräger B. Lignans as food constituents with estrogen and antiestrogen activity. Phytochemistry. 2011; 72(18): 2396-405. https://dx.doi.org/0.1016/j.phytochem.2011.08.013
  22. Burgberger M, Mierziak J, Augustyniak B, Wojtasik W, Kulma A. The power of lignans: plant compounds with multifaceted health-promoting effects. Metabolites. 2025; 15(9): 589. https://dx.doi.org/10.3390/metabo15090589
  23. Parish S.J., Simon J.A., Davis S.R., Giraldi A., Goldstein I., Goldstein S.W. et al. International society for the study of women’s sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J. Sex. Med. 2021; 18(5): 849-67. https://dx.doi.org/10.1016/j.jsxm.2020.10.009
  24. Clayton A.H., Kingsberg S.A., Goldstein I. Evaluation and management of hypoactive sexual desire disorder. Sex. Med. 2018; 6(2): 59-74 https://dx.doi.org/10.1016/j.esxm.2018.01.004
  25. Parish S.J., Cottler-Casanova S., Clayton A.H., McCabe M.P., Coleman E., Reed G.M. The evolution of the female sexual disorder / dysfunction definitions, nomenclature, and classifications: a review of DSM, ICSM, ISSWSH, and ICD. Sex. Med. Rev. 2021; 9(1): 36-56. https://dx.doi.org/10.1016/j.sxmr.2020.05.001
  26. Taranto P., de Brito Sales D., Maluf F.C., Guendelmann R.A.K., de Melo Pompei L., Leal A. Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy. Breast Cancer Res. 2024; 26(1): 133. https://dx.doi.org/10.1186/s13058-024-01886-7
  27. Eapen R.S., Radomski S.B. Gender differences in overactive bladder. Can. J. Urol. 2016; 23(Suppl 1): 2-9.
  28. Russo E., Caretto M., Giannini A., Bitzer J., Cano A., Ceausu I. et al. Management of urinary incontinence in postmenopausal women: an EMAS clinical guide. Maturitas. 2021; 143: 223-30. https://dx.doi.org/10.1016/j.maturitas.2020.09.005
  29. Cho S.T., Kim K.H. Pelvic floor muscle exercise and training for coping with urinary incontinence. J. Exerc. Rehabil. 2021; 17(6): 379-87. https://dx.doi.org/10.12965/jer.2142666.333
  30. NICE Guidance – Urinary incontinence and pelvic organ prolapse in women: management: ©NICE (2019) Urinary incontinence and pelvic organ prolapse in women: management. BJU Int. 2019; 123(5): 777-803. https://dx.doi.org/10.1111/bju.14763
  31. Kobashi K.C., Vasavada S., Bloschichak A., Hermanson L., Kaczmarek J., Kim S.K. et al. Updates to surgical treatment of female stress urinary incontinence (SUI): AUA/SUFU Guideline. J. Urol. 2023; 209(6). 1091-8. https://dx.doi.org/10.1097/JU.0000000000003435
  32. Yao H., Zhang X., Sun F., Tang G., Wu J., Zhou Z. The efficacy of intravaginal electrical stimulation (IVES) in treating female with urinary incontinence symptom from meta-analysis of nine randomized controlled trials. Front. Neurol. 2022; 13: 933679. https://dx.doi.org/10.3389/fneur.2022.933679
  33. Cameron A.P., Chung D.E., Dielubanza E.J., Enemchukwu E., Ginsberg D.A., Helfand B.T. et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J. Urol. 2024; 212(1): 11-20. https://dx.doi.org/10.1097/JU.0000000000003985
  34. Webber L., Davies M., Anderson R., Bartlett J., Braat D., Cartwright B. et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016; 31(5): 926-37. https://dx.doi.org/10.1093/humrep/dew027
  35. Li M., Zhu Y., Wei J., Chen L., Chen S., Lai D. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023; 26(2): 95-102. https://dx.doi.org/10.1080/13697137.2022.2153033
  36. Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. ESHRE, Evidence-based guideline: premature ovarian insufficiency. Hum. Reprod. Open. 2024; 2024(4): hoae065. https://dx.doi.org/10.1093/hropen/hoae065
  37. Chon S.J., Umair Z., Yoon M.S. Premature ovarian insufficiency: past, present, and future. Front. Cell Dev. Biol. 2021; 9: 672890. https://dx.doi.org/10.3389/fcell.2021.672890
  38. Xi D., Chen B., Tao H., Xu Y., Chen G. The risk of depressive and anxiety symptoms in women with premature ovarian insufficiency: a systematic review and meta-analysis. Arch. Womens Ment Health. 2023; 26(1): 1-10. https://dx.doi.org/10.1007/s00737-022-01289-7
  39. McDonald I.R., Welt C.K., Dwyer A.A. Health-related quality of life in women with primary ovarian insufficiency: a scoping review of the literature and implications for targeted interventions. Hum. Reprod. 2022; 37(12): 2817-30. https://dx.doi.org/10.1093/humrep/deac200
  40. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020; 27(9): 976-92. https://dx.doi.org/10.1097/GME.0000000000001609
  41. Carlson K., Nguyen H. Genitourinary syndrome of menopause. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;
  42. Kapoor E. Premature ovarian insufficiency. Curr. Opin. Endocr. Metab. Res. 2023; 28: 100435. https://dx.doi.org/10.1016/j.coemr.2023.100435
  43. European Society of Human Reproduction and Embryology. Guideline on premature ovarian insufficiency. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Premature-ovarian-insufficiency
  44. Calik-Ksepka A., Grymowicz M., Rudnicka E., Skórska J., Machura P., Pięta W. et al. Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency. Prz. Menopauzalny. 2018; 17(3): 131-4. https://dx.doi.org/10.5114/pm.2018.78558
  45. Panay N., Anderson R.A., Nappi R.E., Vincent A.J., Vujovic S., Webber L. et al. Premature ovarian insufficiency: an International menopause society white paper. Climacteric. 2020; 23(5): 426-46. https://dx.doi.org/10.1080/13697137.2020.1804547
  46. British Menopause Society. BMS Consensus Statement. Premature ovarian insufficiency POI. Available at: https://thebms.org.uk/wp-content/uploads/2024/04/05-BMS-ConsensusStatement-Premature-ovarian-insufficiency-POI-APRIL2024-C.pdf
  47. Palacios S., Nappi R.E., Bruyniks N., Particco M., Panay N. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018; 21(3): 286-91. https://dx.doi.org/10.1080/13697137.2018.1446930
  48. Nappi R.E., Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014; 17(1): 3-9. https://dx.doi.org/10.3109/13697137.2013.871696
  49. Vazirani A., Ravichandiran N. Prevalence of menopausal symptoms and their health seeking behavior in postmenopausal women in a tertiary care hospital. J. Obstet. Gynecol. Cancer Res. 2024; 9(4): 385-94.
  50. Palacios S. Sequential treatment in vulvovaginal atrophy. Climacteric. 2023; 26(4): 292-5. https://dx.doi.org/10.1080/13697137.2023.2197588
  51. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2025. Доступно по: https://drive.google.com/file/d/143g7Dfbg5-EpnCwRfNarLPNIH_X7LItw/view [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and menopausal syndrome in women. 2025. Available at: https://drive.google.com/file/d/143g7Dfbg5-EpnCwRfNarLPNIH_X7LItw/view (in Russian)].
  52. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Аменорея и олигоменорея. 2024. Доступно по: https://cr.minzdrav.gov.ru/view-cr/644_2 [Ministry of Health of the Russian Federation. Clinical guidelines. Amenorrhea and oligomenorrhea. 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/644_2 (in Russian)].
  53. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Остеопороз. 2021. Доступно по: https://legalacts.ru/doc/klinicheskie-rekomendatsii-osteoporoz-utv-minzdravom-rossii/ [Ministry of Health of the Russian Federation. Clinical guidelines. Osteoporosis. 2021. Available at: https://legalacts.ru/doc/klinicheskie-rekomendatsii-osteoporoz-utv-minzdravom-rossii/ (in Russian)].

Received 04.02.2026

Accepted 13.02.2026

About the Authors

Tatiana A. Teterina, PhD, obstetrician-gynecologist, USD Specialist,, Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 4, Ac. Oparina str., Moscow, Russia, 117997; Expert of the Association of Specialists in Aesthetic Gynecology, palpebra@inbox.ru, https://orcid.org/0000-0003-0990-2302
Inna A. Apolikhina, Honored Doctor of the Russian Federation, Dr. Med. Sci., Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation, Professor at the Department of Obstetrics and Gynecology, Department of Vocational Education, V.I. Kulakov National Medical Research Center of the Ministry of Health of Russia, 4, Ac. Oparina str., Moscow, Russia, 117997; Professor, Department of Obstetrics, Gynecology, Perinatology and Reproductology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); President of the Association of Specialists in Aesthetic Gynecology, i_apolikhina@oparina4.ru,
https://orcid.org/0000-0002-4581-6295
Maria I. Yarmolinskaya, Honored Scientist of the Russian Federation, Professor of the RAS, Dr. Med. Sci., Professor, Head of the Department of Gynecology and Endocrinology, Head of the Center for Diagnosis and Treatment of Endometriosis, Head of the Scientific and Practical Center of Gynecological Endocrinology, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproduction, 3 Mendeleevskaya line, St. Petersburg, Russia, 199034; Professor, Department of Obstetrics and Gynecology, I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia; President of the Society of Obstetricians and Gynecologists of St. Petersburg and the Northwestern Federal District, m.yarmolinskaya@gmail.com, https://orcid.org/0000-0002-6551-4147
Khava B. Balashova, оbstetrician-gynecologist, postgraduate, Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 4, Ac. Oparina str., Moscow, Russia, 117997, Hava199@mail.ru, https://orcid.org/0000-0003-3365-4695

Similar Articles

№10 / 2025
Mkrtchian L.S., Kukosh M.Yu., Bychkova A.E., Apolikhina I.A., Ivanov S.A., Kaprin A.D., Zamulaeva I.A.
Hyaluronic acid in the correction of genitourinary syndrome of menopause in women after anticancer treatment
№11 / 2024
Managadze I.D., Nesterova A.A., Levakova O.S., Levakov S.A.
Psychoemotional aspects and somatic status of women with endometriosis: is there a link?
№3 / 2025
Lyashenko E.N., Malovichko V.S., Epifanova I.A.
The relationship between endometriosis and infertility: diagnostic methods and treatment
№2 / 2026
Ermakova E.I., Smetnik A.A., Ivanov I.A.
Experience of clinical use of non-hormonal cream Triofemin to control the symptoms of genitourinary syndrome of menopause/vulvovaginal atrophy in peri- and postmenopausal patients
№11 / 2025
Klinyshkova T.V.
Oncological aspects of endometrial polyps in peri- and postmenopausal women
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.